

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

VOLUNTARY ANNOUNCEMENT PROPOSED BID-WINNING RESULTS OF NATIONAL CENTRALISED PROCUREMENT OF PHARMACEUTICALS (SPECIALISING RENEWAL IN INSULIN)

This announcement is made by The United Laboratories International Holdings Limited (the “Company”) on a voluntary basis.

The board of directors of the Company is pleased to announce that, on 23 April 2024, Zhuhai United Laboratories Co., Ltd. (珠海聯邦制藥股份有限公司) and Zhuhai United Laboratories Co., Ltd., Zhongshan Branch (珠海聯邦制藥股份有限公司中山分公司), a wholly-owned subsidiary of the Company, participated in the bidding for the National Centralised Procurement of Pharmaceuticals (specialising renewal in insulin) (“specialising renewal in insulin”) organised by the National Organization Office for Centralised Procurement of Pharmaceuticals. The insulin products of the Company are expected to win the bidding in this centralised procurement. The relevant information is now disclosed as follows:

Basic Information of the Company’s Proposed Bid-winning Products

No. of Procurement Group	Name of Procurement Group	Name of Products	Specification and Packaging	Tendering Price (RMB/vial)	Price Change	Selected Category	Basic volume of procurement (vial)*
1	Mealtime Insulin	Human Insulin Injection	3ml: 300 units (refilled pen-type)	25.91	-9.9%	A	783,000
2	Basal Insulin	Protamine Insulin Injection	3ml: 300 units (refilled pen-type)	25.91	-11.8%	A	182,600
3	Premixed Insulin	Protamine Insulin Mixed Injection (30R/50R)	3ml: 300 units (refilled pen-type)	25.91	-5.3%	A	10,083,700
4	Mealtime Insulin Analogue	Insulin Aspart Injection	3ml: 300 units (refilled pen-type)	25.91	-37.2%	A	940,400
5	Basal Insulin Analogue	Insulin Glargine Injection	3ml: 300 units (refilled pen-type)	65.31	-2.5%	A	4,155,900
6	Premixed Insulin Analogue	Insulin Aspart 30 Injection	3ml: 300 units (refilled pen-type)	25.91	-37.2%	A	2,546,400

Notes:

1. The prices of pre-filled insulin (3ml: 300 units) increase by RMB5 per vial in category A and RMB3 per vial in categories B and C on the basis of tendering prices of representative products specifications (3ml: 300 units (refilled pen-type)) in the same quotation unit of the company.
2. The agreed volume for procurement of the selected products is generated in two steps:
 - (1) *Obtained basic volume: within the same procurement group, each product will obtain basic volume in a certain proportion to its first year's purchasing demand according to its ranking and category.
 - (a) The basic volume proportion of selected products in category A1 to their first year's purchasing demand is 100%, and the proportion of other selected products in category A is 80%. The basic volume proportion of selected products in category B to their first year's purchasing demand is 55%. The basic volume proportion of selected products in category C to their first year's purchasing demand is 45%.
 - (b) If selected products in each procurement group have upgraded or maintained in category A comparing with their first round of centralised procurement, the proportion of their obtained basic volume to their first year's purchasing demand will increase by an additional 10%. On the contrary, reduce by 10%.
 - (2) Allocated remaining volume: within the same procurement group, the unallocated purchasing demand of the selected products in categories B and C and the purchasing demand of the unselected products are remaining volume, which will be independently selected by medical institutions among the selected products in category A.

The expected impact of the proposed bidding on the Company

All insulin products of the Company have participated in the bidding of centralised procurement of insulin and all products were proposed to win the bid in category A. The revenue of the Company's proposed bid-winning products was RMB1,117,600,000, accounting for 22.2% of the Company's finished products revenue in 2023.

According to the rules for specialising renewal in insulin, the centralised procurement cycle will start from the date of execution of the bidding results to 31 December 2027. Medical institutions will give priority to the use of selected drugs in this centralised procurement and ensure the completion of the agreed procurement volume. Compared with the Sixth National Centralised Procurement of Pharmaceuticals (specialising in insulin), the price of the Company's proposed bid-winning products is moderately downward, but the basic purchasing volume has increased significantly by 52.5%. At the same time, all the Company's bidding products in category A will obtain allocated remaining volume. This bid-winning will help the Company to expand the sales of the above products, enhance the market share of insulin products, and at the same time, continuously improving the affordability of diabetes products, benefit the diabetic patients, and have a positive impact on the Company's brand influence as well as the future business development.

By Order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 23 April 2024

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Prof. Song Ming and Dr. Fu Qiushi as independent non-executive directors.